Trichostatin A (TSA)

製品コードS1045

Trichostatin A (TSA)化学構造

分子量(MW):302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

サイズ 価格(税別)  
JPY 41002.00
JPY 74202.00
JPY 144420.00

カスタマーフィードバック(6)

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
ターゲット
HDAC [1]
(Cell-free assay)
~1.8 nM
体外試験

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 Mkn1SpVv[3Srb36gRZN{[Xl? MViwMlfPxE1? M2LF[FI1cA>? M3ezZoV1cGGwb3y= NWTEbFdq\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= MUiyOVc5PzB5OR?=
TE13 M3vWOWZ2dmO2aX;uJGF{e2G7 MVewMlPPxE1? NW\4W4w{OjSq NE\QNIN2eC2{ZXf1cIF1\XNiUlHTV2Y2SSCuZY\lcC=> NFTBengzPTV5OU[2OS=>
TE13 NX[wWmtNSXCxcITvd4l{KEG|c3H5 MnnqNE4{|ryP M2L3XVI1cA>? NHPjcZRqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w M4TRbVI2PTd7Nk[1
MEFs NV[5clBTTnWwY4Tpc44hSXO|YYm= NFLmS|k2|ryP NFXJOY0yPmh? NHKxUFBqdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25? MmH0NlU1QDJ4M{S=
SW480  MVTGeY5kfGmxbjDBd5NigQ>? NX6wXHF1OC5zzszN MU[0PIg> M3jhOWROW09? M{HBXZJmfmW{c3XzJGVOXA>? M{eyR|I2PDN2OUm3
PC3  NXfyUXVnTnWwY4Tpc44hSXO|YYm= MnLFNE4y|ryP NEXTNoY1QGh? M33uZmROW09? M4fkeZJmfmW{c3XzJGVOXA>? MX2yOVQ{PDl7Nx?=
SW480  NHSzWXNHfW6ldHnvckBCe3OjeR?= M3vENVAvOc7:TR?= NUfuO4xvPDiq NXrDeJJYTE2VTx?= NEfmc2xifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= NEnRemozPTR|NEm5Oy=>
PC3  NVfDeVNJTnWwY4Tpc44hSXO|YYm= NV7FeWVmOC5zzszN Mo\LOFhp Mnr6SG1UVw>? NHvuV4lifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= NFi5S48zPTR|NEm5Oy=>
SW480  MmLlSpVv[3Srb36gRZN{[Xl? NEX6O5ExNjIQvF2= MVe0PIg> NWrZdYl{TE2VTx?= NHvrWlNqdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ M3vzN|I2PDN2OUm3
PC3  NWTjdnJ6TnWwY4Tpc44hSXO|YYm= M{W4eVAvOc7:TR?= MV[0PIg> NGfLVJRFVVOR Mln0bY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? MnTtNlU1OzR7OUe=
A431 M4LWTWFxd3C2b4Ppd{BCe3OjeR?= NWLBNHJIOi9zMD:1NE8yODCwTR?= M3HzSVQ5cA>? MUjEUXNQ NUO2c2YzcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4To MnT3NlU{PzFyNkm=
A431 M{fIN2Z2dmO2aX;uJGF{e2G7 M1Hv[FUxdk1? NXSzVXJ3Oi94L{GyM|I1cA>? NXzJUlVHTE2VTx?= M{T1O4FkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?= MX[yOVM4OTB4OR?=
MDA-MB-231 NHPOTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmwMVYxOG6P M1fJRlI1cA>? MWfEUXNQ NVfpeHJ7UUN3MDDv[kAyODCwTR?= NVPXN293OjVzOUK3NlE>
MCF7 M{\xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmwMVYxOG6P M3XpU|I1cA>? MlSySG1UVw>? M3HU[2lEPTBib3[gO|VvVQ>? MXKyOVE6Ojd{MR?=
SKOV-3 MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqxMVEx|ryP Mo\KNlRp NHLYcnlFVVOR MUnJR|UxKG:oIEWuOu69VQ>? NIL6UWozPTF4OUS5NS=>
A549 NHHJN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCxMVEx|ryP MnqwNlRp MWHEUXNQ MYXJR|UxKG:oIEOuNu69VQ>? MV:yOVE3QTR7MR?=
SKOV-3 NVzLdGtCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fkcFAvOS1zzszN NXXKXGo2PDiq NGjvS3FFVVOR MUjJR|UxKG:oIECuO:69VQ>? NHXJRYIzPTF4OUS5NS=>
A549 M3fUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPCXJpOOC5zLUJOwG0> NXXCZ3htPDiq NH73dHVFVVOR M3\yR2lEPTBib3[gNE4zQM7:TR?= NUjWWnhnOjVzNkm0PVE>
SKOV-3 NWTpOZVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH60TW0xNjBzLUCuPe69VQ>? MknTO|Jp NYnRTohHTE2VTx?= MoruTWM2OCCxZjCwMlMz|ryP M4PrT|I2OTZ7NEmx
A549 M2\kVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7KNE4xOS1yLkpOwG0> NIn6Tok4Omh? NISyfm9FVVOR MmXVTWM2OCCxZjCwMlA3|ryP MXSyOVE3QTR7MR?=
HeLa M17PbmZ2dmO2aX;uJGF{e2G7 M2H2OlI2OG6P M4D1c|E3cA>? MoG1SG1UVw>? NYXkTlhEcW6lcnXhd4V{KEO\UEHBNUBuWk6DIHX4dJJme3Orb39CpC=> MoTYNlUyOTZ4OEi=
CNE2 NFfUb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e2ZlExOC14MEDuUS=> M3nFXFI1NzR6L{eybC=> MXzpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M{nBSlI1QTZ7OUCx
PC3 NYPiZoNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;vNVAxNTFyMEDuUS=> NHf0ZlUzPGh? MWPJR|UxKG:oIEOwNI5O NU\rfHZiOjR6NUS2OVg>
LNCaP M{PKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVqwV3RJOTByLUGwNFBvVQ>? M2HwO|I1cA>? M{XEWWlEPTBib3[gN|Axdk1? NEXoUoQzPDh3NE[1PC=>
HeLa  M2KxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PnNVLPxE1? M{OzbFQ5cA>? NXK0XZlp\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIFjd3W2IEK1KS=> NEDJbVIzPDh2NkGzOS=>
HMEC-1  Mm\mSpVv[3Srb36gRZN{[Xl? M1;wO|MxOG6P MXqyOIg> NG\ZXo5qdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZtMgWmVITlJ|wrDtVm5C MXeyOFcyODZ|MR?=
HeLa MYXGeY5kfGmxbjDBd5NigQ>? MX[xcW0> NVK3NVluOC53aB?= MYjhZo9tcXOqZYOgeIhmKHSxdHHsJGhFSUNiYXP0bZZqfHl? M1X6R|I1PzB5NEe0
ACP02 NF6xcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTVNlUxNzN3MD:1NFBvVQ>? MnSyNlRp NGCxNphl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P MUGyOFY3QDV2Nx?=
ACP03 NVP3NlR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[yOVAwOzVyL{WwNI5O MWiyOIg> MUXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlib3[gZZBxem:6aX3heIVtgSB5MNMgKUBifCB{NUFCpI5O NHPFVoQzPDZ4OEW0Oy=>
U87 GBM MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTtdWEyODBxM{CwM|UxOCCwTR?= NXfLb4FCPzJiaB?= NI\LfnkyODBnIHX0bIFvd2x? MlvmdoVlfWOnczDt[YFvKGOnbHygcpVu[mW{IHL5JFMyNCB3NDygZY5lKDV6wrCl NUTZO45kOjR2NkS4OFE>
U87 GBM NVHKOJA4TnWwY4Tpc44hSXO|YYm= NEezWZcyODBxNUCwJG5u NGrQTGo1QCCq MUKxNFAmKGW2aHHuc4w> MkmxTY5lfWOnczDT[Y5me2OnbnPlMWxqc2ViQXz0[ZJifGmxboOgbY4hVnWlbHXhdkBOd3KyaH;sc4d6 Ml35NlQ1PjR6NEG=
RPE M1nzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXWNmsxNjJxMD60M|AvQC9zIN88US=> M4SyTFI1NzR6L{eyJIg> NIjXPHNFVVOR NUiwbGtCcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44h[nliY3XscEBkgWOuZTDhdpJme3R? MY[yOFQ2PjZyMh?=
HT29  MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXlVYMyQDBibl2= MkK2O|IhcA>? MULJR|UxKG:oIEG4NEBvVQ>? M3\XVVI1OzZ6Mk[1
hMSCs NVHqOXVETnWwY4Tpc44hSXO|YYm= M1;idlYvOjVibl2= MkDXNlQhcA>? Mnq3SG1UVw>? Mm\3d5Ri[mmuaYrld{BJcXO2b37lJGFk\XS7bHH0bY9vKGGwZDD0bIUhTXiycnXzd4lwdiCxZjDQcJVzcXCxdHXueEBI\W6ncx?= NGjNNVQzPDNzMkO1Oi=>
Huh7  NUDtdVlrTnWwY4Tpc44hSXO|YYm= MmT3NE4yNzBwNT:xMlAh|ryP MXyyOIg> NHLXPVZ{fXCycnXzd4V{KFmWSFTDNkBo\W6nIHX4dJJme3Orb36= MlnrNlQzPjl4N{K=
SKOV3 NXjoTXI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT2OVgxNjB3LUKg{txO M1K0NFExNzJ2L{S4JIg> MYPEUXNQ M4K4WY1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MnGyNlQzOjN6MEG=
A2780 Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXmwMlA2NTJizszN NHnsNFgyOC9{ND:0PEBp MVXEUXNQ M2S1bI1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MX6yOFIzOzhyMR?=
SRA01/04  M3XJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn1NE4zKM7:TR?= M3;zNlQ5KGh? NHzQelhFVVOR MnXvd5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> NFLNNWkzPDF3N{i3PC=>
HLEB3 MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonJNE4zKM7:TR?= MXm0PEBp MmrHSG1UVw>? M{f6eZN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ NF7MXZkzPDF3N{i3PC=>
SRA01/04  MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSwMlQwOC56IN88US=> M1O2clQ5KGh? M2PHVmROW09? M1vOfYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NX\hSplmOjRzNUe4O|g>
HLEB3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXXNE41NzBwODFOwG0> NHnicoo1QCCq M2HIVGROW09? M{DUeIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MXuyOFE2Pzh5OB?=
HCT116 NXXS[3pXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGwMlIh|ryP MmDyNVIhcA>? MmTR[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDyZYRq[XSrb36= M4O4[|I1OTJ{MkOx
CA46 M2PHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3znb|MwPi9zMj:yOE81QCCwTR?= NFv0WXQ1QCCq MoDRbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCjdDCyOEBidmRiNEigcm3DqA>? NXLEZmVqOjRyNkS5OVE>
PMNs NVXqU2QxTnWwY4Tpc44hSXO|YYm= NEjoOoE{OCCwTR?= MkTWOFghcA>? MkmxbY5pcWKrdIOg[YZn\XKxY4n0c5NqeyxiSFTBR{Bi[3Srdnn0fUBidmRiUnHjJIFkfGm4aYT5 NECxcWMzOzl6OE[xOy=>
H1299 NGfvPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3iTYFYOcLizszNxsA> NEDQNoczPC92OD:3NkBp MYXleIhidm:u M{i5bIlv[3KnYYPld{Bk\WyuIHTlZZRpKGGodHXyJFI1cA>? MUSyN|kyPjZyOR?=
A549 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGwMlI2NzBwNT:xJO69VQ>? MVqyOE81QC95MjDo MVHleIhidm:u Mn3lbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MUKyN|g3Pzl7MR?=
H1299 NVvFT|dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYewMlI2NzBwNT:xJO69VQ>? NEezenEzPC92OD:3NkBp M{jxN4V1cGGwb3y= M3HGbYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NXfmfHUxOjN6Nke5PVE>
A549 NI\tWJJCeG:ydH;zbZMhSXO|YYm= MnuyNE42NzFizszN M4KzTFQ5KGh? NIPjZ4lmfGijbn;s MoPabY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? Mm\ENlM5Pjd7OUG=
H1299 NE\3OlNCeG:ydH;zbZMhSXO|YYm= M3\H[|AvPS9zIN88US=> NWPnS4x1PDhiaB?= Ml\2[ZRp[W6xbB?= NX\oc4JJcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M3\ZOVI{QDZ5OUmx
SUM149PT NH7lWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L0UVIwPy53L{GwJO69VQ>? Ml\LOFghcA>? Mk\pSG1UVw>? NFrxRXhqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6|ZX7zbZRqfmWueR?= MnnENlM4QTJ4M{i=
SUM190PT NITmVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojoOVAwOTByL{K1NEBvVQ>? M4W4RlQ5KGh? MmDtSG1UVw>? NV3wdIVxcW6mdXPld{Bk\WyuIHTlZZRpKGG2IEWwJI5OKHOnboPpeIl3\Wy7 NFf1b2IzOzd7Mk[zPC=>
HCT1 M1HJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;NNIIxNjJxMT6wM|UvOCEQvF2= M33lVlEzNzJ2L{O2M|Q5KGh? MVTpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= Mo\MNlM4PzByMEC=
Lovo NUnNWnlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV73WldCOC5{L{GuNE82NjBizszN NFe4S4EyOi9{ND:zOk81QCCq M4TxRolv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MlG5NlM4PzByMEC=
AGS MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLyRWgxNjBzNT2xJO69VQ>? NYn3[3dIPzJiaB?= MnHTbY5lfWOnczDj[YxtKGSnYYToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MlWxNlM4PDVyMkS=
Huh7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoqxNUDPxE1? NGOz[FczPCCq MXXEUXNQ NVTCR3Y2emWmdXPld{Bi[m:3dDCyNEUhfmmjYnnsbZR6yqB? NWXEeXJEOjN4NEO5N|M>
ECC1 MU\GeY5kfGmxbjDBd5NigQ>? NFn5cm02ODBibl2= M1:4[|Uh\A>? MWLEUXNQ MmP0bY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? M{jUbVI{PTNyN{[5
HEC1A M4HSPGZ2dmO2aX;uJGF{e2G7 MYi1NFAhdk1? NF3qNFI2KGR? MkjZSG1UVw>? NFHZWpRqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NFnjdI4zOzV|MEe2PS=>
EN1 MWHGeY5kfGmxbjDBd5NigQ>? MUW1NFAhdk1? MlnTOUBl NIPSNJNFVVOR MUPpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NGnwNY8zOzV|MEe2PS=>
MFE296 M4K5UmZ2dmO2aX;uJGF{e2G7 NGPaR2s2ODBibl2= NH35T2s2KGR? MYLEUXNQ M1XPNYlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NUjt[JdiOjN3M{C3Olk>
HASMCs NVLhb4hbTnWwY4Tpc44hSXO|YYm= MXSwMVUxOCCwTR?= NVi5PFZFPiCm MYjkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKQVTDJIFv\CClZXzsJJZq[WKrbHn0fS=> M1zhSFI{PTF6NE[3
U373 M2rwcGZ2dmO2aX;uJGF{e2G7 MmjwNE4zPS9yLkWvNUDPxE1? MW[yOEBp NFu1TGpqdmO{ZXHz[ZMhWFJvQjDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFVCgmGmQx?= NWi5[29TOjN2N{SxO|E>
ARN8  MnG1SpVv[3Srb36gRZN{[Xl? M1f1e|AvODVvMjFOwG0> NIjtRnEzPCCq M1HHUZJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDwOVMu\GWyZX7k[Y51KGenbnXzJIJ6KE63dHzpck0{ M2nkXlI{PDdyNUSw
MCF7 MoPYSpVv[3Srb36gRZN{[Xl? NYrFc4pHOC5yNT2yJO69VQ>? M4HRcFI1KGh? NV7COm8xemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NEO4T3YzOzR5MEW0NC=>
H1299  MmLPSpVv[3Srb36gRZN{[Xl? NWH2TW1KOC5|M,MAl|HDqML3TR?= MlnXNlQwPDhiaB?= MULEUXNQ MVHpcoNz\WG|ZYOgSU1k[WSqZYLpckBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7 NHPKS5kzOzR4MUm3OS=>
H1299 M{nMV2Z2dmO2aX;uJGF{e2G7 NFL4c|gxNjVizszN MYi0PEBp NXPxbJJQTE2VTx?= NXnVdIlUcW6qaXLpeJMhfGinIH3p[5JifG:{eTDwc5RmdnSrYXygZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? Mkf6NlM1PjF7N{W=
H1299 MXzGeY5kfGmxbjDBd5NigQ>? Ml;CNE42KM7:TR?= NFz6NIk1QCCq MlnESG1UVw>? M4LlU4lvcGmkaYTzJJRp\SCrbo\hd4l3\W6nc4RCpEBkd22kaX7lJJdqfGhic3nsbYJqdmmw NE\yVFgzOzR4MUm3OS=>
MG-63  M{S5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonjNE4{KM7:TR?= MUOxNk06PiCq MXfEUXNQ MYPpcohq[mm2czD0bIUh[2WubDDndo94fGhiY3:teJJm[XSvZX70JJdqfGhibXX0[o9zdWmw NEe0R4kzOzR3MUixOy=>
LM8 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:5NE4{KM7:TR?= NWXX[5p1OTJvOU[gbC=> NX\hVVBNTE2VTx?= M4XQSIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= M4m5NVI{PDVzOEG3
K562 MXjGeY5kfGmxbjDBd5NigQ>? MkLlNE42KM7:TR?= NH7BToozPCCq M4n5TIV1cGGwb3y= NVnWbJFT\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? MVeyN|Q{ODl3Nx?=
HEL MojpSpVv[3Srb36gRZN{[Xl? MmS5NE42KM7:TR?= Mor3NlQhcA>? MX7leIhidm:u M37vRoRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv MnPjNlM1OzB7NUe=
HL60 MlvzRZBweHSxc3nzJGF{e2G7 M4nYNFEh|ryP M3fQWlI1KGh? NV2wXYp4cW6mdXPld:Kh[2WubDDk[YF1cA>? MlvzNlM1ODB3MUm=
KG1 NVX4VoZwSXCxcITvd4l{KEG|c3H5 MV6xJO69VQ>? Ml2zNlQhcA>? MonabY5lfWOnc9MgZ4VtdCCmZXH0bC=> MYCyN|QxODVzOR?=
Kazumi NF7KVHZCeG:ydH;zbZMhSXO|YYm= MlHoNUDPxE1? Mk\aNlQhcA>? MWrpcoR2[2W|wrDj[YxtKGSnYYTo MVmyN|QxODVzOR?=
K562 MmnLRZBweHSxc3nzJGF{e2G7 NGj6dmQyKM7:TR?= M3nBVVI1KGh? MkO5bY5lfWOnc9MgZ4VtdCCmZXH0bC=> M{nYcFI{PDByNUG5
THP1 NUjySWFoSXCxcITvd4l{KEG|c3H5 NIjOeowyKM7:TR?= MkDSNlQhcA>? M2XXO4lv\HWlZYRCpINmdGxiZHXheIg> NEXGO4szOzRyMEWxPS=>
SH-SY5Y NFnCOXhHfW6ldHnvckBCe3OjeR?= NIrLN5ozPTBibl2= NFLCNXMyPiCq M2DHTINp[W6pZYOg[ZhxemW|c3nvckBx[XS2ZYLuJI9nKGenbnXzJIlvfm:udnXkJIlvKGOqb3zld5Rmem:uIIP5cpRp\XOrczygeZB1[WunIHHu[EBm\m[udYi= M4jhbVI{OzJ4NEKy
HEK293 NFHDWmVHfW6ldHnvckBCe3OjeR?= M{j6TFEhyrWPwrC= M4C0RVE5KGkEoB?= NHHFeW9qdmirYnn0d{B1cGVia3HsbZJqdi15LX3l[IlifGWmIILlZ5J2cXSvZX70JI9nKHO7boDobYxqdi1zIHHn[5Jm\2G2ZYOgbY51dyCjZ3fy[ZNwdWW| Ml2yNlMzQDR6NEi=
HTK M3HQNGZ2dmO2aX;uJGF{e2G7 MkPwOFAxKG6P NEHyVJg4OiCq NFm2NFlqdmirYnn0d{BVT0ZvzsNihLNKdmS3Y3XkJG16d2[rYoLvZoxie3RiRHnm[oVz\W62aXH0bY9v MW[yN|I5PDByMh?=
HTK M1Tve2Z2dmO2aX;uJGF{e2G7 M1i1dFExOC16MEDuUS=> NVTjZnliPzJiaB?= NXvQNWd4[myxY3vzJHRITi4QsvMAl2lv\HWlZXSgVm9UKGGwZDDINm8zyqCDY3P1cZVt[XSrb36= NFv0[ZYzOzJ6NECwNi=>
Caco-2  M4LucmZ2dmO2aX;uJGF{e2G7 MlTiNUDDvU4EoB?= MXKyOEBp MlTh[IVkemWjc3XzJHNGWlRicILveIVqdiCneIDy[ZN{cW:w M{PGbVI{OTl3MEew
HeLa MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zWZlExOCCwTR?= NGnOWo0zPCCq M4PI[2ROW09? MXfJR|UxKG:oIEGwNI5O MUmyN|E3PTd2OB?=
HeLa NIrxUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPTPGg1OCCwTR?= Mk\WOFghcA>? NFrLWHJFVVOR M1;hNmlEPTBib3[gOFBvVQ>? NI\ISFgzOzF4NUe0PC=>
HeLa M{TVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;sOpYzOCCwTR?= M{n5UlczKGh? MV;EUXNQ NFXDZZhKSzVyIH;mJFIxdk1? M33lOFI{OTZ3N{S4
HeLa MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7hNVAwOzBxNUCgcm0> MWe3NkBp MYTEUXNQ MVrpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCPTWCgLO6V|qivKTDsc5N{KGOnbHzzJIRwe2ViZHXw[Y5l\W62bIm= MXyyN|E3PTd2OB?=
MDA-MB-231 NVi1W3o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fGfFI2NTRyMDDuUS=> MkiyOFghcA>? NXj2Z5JqUUN3MDDv[kAzPjNwMn7NxsA> MWSyN|A2PTF7OB?=
MCF-7  MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVGyOU01ODBibl2= M13PWVQ5KGh? NXfyfnpnUUN3MDDv[kAzOjBwNH7N MmfuNlMxPTVzOUi=
ECC-1  NWXObldiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[2NVAxKG6P M3G2VlI1KGh? MVLleIhidm:u MWDpcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{PSV? NGnPd2MzOzB{OEiwNy=>
HEC-1A MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnYNVAxKG6P Mn;PNlQhcA>? M3GzTIV1cGGwb3y= NYO2bFEycW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{ml NYXvRpZlOjNyMki4NFM>
NHAC-kn MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHyNVAwOTByL{WwNEBvVQ>? MVqxNkBp NXe1NnlGTE2VTx?= Ml3YTWM2OCCxZjC1NFBvVQ>? MmT4NlMxOTd6N{G=
A549 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DOS|I2OCCwTR?= MoXrOk04OiCq MkmySG1UVw>? MWXjZZV{\XNiYTDndoVifGW{IHnubIljcXSxcomg[YZn\WO2IHPvcYJqdmVid3n0bEBVYFRib4Kg[ZJtd3Srbnni NVuzPYprOjJ7OUS3PFA>
MG-63 NI\qS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nTW|MxOCCwTR?= NUn6O5kxOTJiaB?= NEPnZVFFVVOR NEnXUYxqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hQDZn MkDZNlI4QTl|M{i=
MG-63 MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf2fJl{OzByIH7N NH7nfYozPCCq MmPQSG1UVw>? NETpb29qdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPjdn NHOwUpEzOjd7OUOzPC=>
MG-63 M4TWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrL[WhlOzByIH7N M{PBclQ5KGh? MXrEUXNQ MmnJbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFU3LQ>? MYOyNlc6QTN|OB?=
HL60  MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\mNVUxNTN3MDDuUS=> MknVNlQhcA>? MkLMbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> NFy3TY4zOjd3M{ezPS=>
U937 Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\2NVUxNTN3MDDuUS=> NWC3RZdKOjRiaB?= M4L4SIlv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> NWnENYhYOjJ5NUO3N|k>
SCC-6 NFLuVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XUcVIxOC1|MkCwJI5O MUOxNk8zPC92ODDo NUK5cWtWTE2VTx?= NETDbodqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBw\iCVQ1OtOkBk\WyuczDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M4XxSlIzPTV{M{Kx
U87  MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLmXHI1OTByLUOwNEBv\w>? MV[yOEBp NEe2dlRqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= MVmyNlI4ODh2OR?=
K562 NHPmfW9HfW6ldHnvckBCe3OjeR?= NV3Tc5VlOSEQvF2= M2OyRVEzKGh? NV\2eWZsTE2VTx?= MWDlcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= MnHmNlIyPzlzOUi=
Reh NYPyXIs6TnWwY4Tpc44hSXO|YYm= M3u3dFAvOy9zIN88US=> MUmxNkBp M{i0SWROW09? M2\UWoVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS NX3IWmlWOjJzN{mxPVg>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
細胞試験:

[1]

+ 展開
  • 細胞株: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • 濃度: Dissolved in absolute ethanol, final concentrations ~10 μM
  • 反応時間: 96 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • 製剤: Dissolved in DMSO
  • 投薬量: ~5 mg/kg/day
  • 投与方法: Injection s.c.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 302.4
化学式

C17H22N2O3

CAS No. 58880-19-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03735173 Not yet recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable
NCT02959905 Unknown status Metastatic Melanoma BGI China|Sun Yat-sen University December 2016 Phase 1
NCT03133819 Enrolling by invitation Diabetes; Neuropathy Polyneuropathy (Manifestation) Chang Gung Memorial Hospital November 2016 Not Applicable
NCT02486965 Recruiting Fibromyalgia University Hospital Brest October 2015 Not Applicable
NCT01954433 Active not recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG) Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Completed Pain Massachusetts General Hospital June 2012 Not Applicable

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • 回答:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Trichostatin A (TSA)を買う | Trichostatin A (TSA) ic50 | Trichostatin A (TSA)供給者 | Trichostatin A (TSA)を購入する | Trichostatin A (TSA)費用 | Trichostatin A (TSA)生産者 | オーダーTrichostatin A (TSA) | Trichostatin A (TSA)化学構造 | Trichostatin A (TSA)分子量 | Trichostatin A (TSA)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID